☰

SOTIO Biotech a.s.

Modernising oncology manufacturing

A biotech advancing ADC and CAR-T oncology pipelines with modernised manufacturing and supply chain control

Industry
Biotechnology (ADC and CAR-T Oncology)
Headquarters
Prague, Czech Republic
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of SOTIO Biotech a.s.'s published strategy and is not endorsed by, or produced in cooperation with, SOTIO Biotech a.s.. Company website

Strategic priorities

SOTIO Biotech a.s. is a Czech biotech company developing Antibody-Drug Conjugates and metabolically enhanced CAR-T therapies targeting global leadership in solid tumour oncology. The company operates across four sites — Prague (manufacturing), Cambridge (R&D), Basel (clinical and regulatory) and 150+ apheresis centres globally — with SOT102 (Claudin 18.2 ADC) and BOXR1030 (GPC3 CAR-T) advancing through multi-centre Phase 1/2 trials. The company is backed by the EUR 44B PPF Group, which provides financial stability alongside mandates around sustainability, 5G/IoT deployment and digital transformation. The immediate challenge is LaSSo legacy MES constraints at the Prague manufacturing site: five terminal PCs serving a 2,000 sqm GMP facility with paper-based hybrid workflows and transcription gaps that create a scalability ceiling as the pipeline advances toward Phase 3 and commercial manufacturing.

The defining challenge is the manufacturing constraint. SCTbio's LaSSo system — a niche solution for SMB manufacturers — lacks enterprise-grade validation under 21 CFR Part 11, complex master data management and integration capabilities. The system cannot scale to handle the master batch record complexity of commercial ADC manufacturing, let alone the chain of identity requirements for autologous CAR-T therapy. Beyond manufacturing, the ADC supply chain requires convergence of three distinct supply chains — antibody, linker and payload — across multiple CDMOs including Biocytogen and Synaffix. Head of CMC describes finding a one-stop-shop CDMO as 'hunting for a unicorn', and current visibility into CDMO inventory and status is limited to manual document exchange.

On the clinical side, SOTIO and SCTbio operate with bifurcated IT systems that prevent real-time visibility into manufacturing and quality data. Patient recruitment for BOXR1030 faces site capacity constraints in a competitive IL-15/CAR-T landscape. The company needs remote digital quality monitoring that reduces the burden of on-site QA oversight as trials scale across 150+ apheresis centres globally.

Challenges we see

  • Operations Manufacturing

    LaSSo MES creating scalability ceiling for Phase 3 and commercial manufacturing

    SCTbio's manufacturing relies on LaSSo — a niche SMB manufacturer system — with five terminal PCs serving a 2,000 sqm GMP facility. Paper-based hybrid workflows and transcription gaps create a scalability ceiling. The system lacks 21 CFR Part 11 validation, complex master data management and integration capabilities required for Phase 3 and commercial manufacturing.

    Where the MES is a paper-based niche system, the master batch record complexity of commercial ADC manufacturing cannot be managed. MES modernisation means the system scales with the pipeline rather than becoming a constraint on it.

  • Operations Supply Chain

    ADC supply chain fragmentation across antibody, linker and payload CDMOs

    ADCs require three distinct supply chains — antibody, linker, payload — across multiple CDMOs. Finding a one-stop-shop CDMO is described as 'hunting for a unicorn'. Current visibility into CDMO inventory and status is limited to manual document exchange, creating stockout and delay risks.

    Where supply chain visibility is limited to manual document exchange, the first sign of a component stockout is a manufacturing line stoppage. A supply chain control tower means the risk is identified and mitigated proactively.

  • Digital Integration

    SOTIO-SCTbio data bifurcation preventing real-time manufacturing-visibility

    SOTIO and SCTbio operate with bifurcated IT systems that prevent real-time visibility into manufacturing and quality data across the two organisations. Manufacturing decisions are made without the real-time data that would enable proactive quality intervention.

    Where manufacturing and quality data are trapped in separate systems, the visibility required for proactive management is absent. Data integration means the right people have the right data at the right time.

  • Compliance Regulatory

    Manual GMP documentation burden consuming QA team capacity

    LaSSo MES limitations mean GMP documentation is partly manual, consuming QA team capacity and creating transcription error risk. As trial scale increases, the documentation burden grows without a corresponding increase in QA headcount.

    Where GMP documentation is manual, the QA team's capacity is consumed by paperwork rather than value-added quality oversight. Digital GMP documentation means QA time is spent on quality judgement rather than form-filling.

  • Commercial Clinical

    Site capacity constraints slowing BOXR1030 patient recruitment

    Patient recruitment for BOXR1030 faces US site capacity constraints in the crowded IL-15/CAR-T competitive landscape. CEO acknowledges recruitment 'remains an arduous task', with CLAUDIO-01 trial eligibility updates indicating struggles identifying optimal patient populations.

    Where patient recruitment is constrained by site capacity, the trial timeline burns cash against a competitive first-mover window. Digital trial site management means the highest-potential sites are prioritised and supported.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. MES modernisation from LaSSo to enterprise GMP platform

    LaSSo's five terminal PCs and paper-based workflows create a scalability ceiling that cannot support Phase 3 and commercial manufacturing. The system lacks 21 CFR Part 11 validation and integration capabilities that enterprise GMP operations require.

    Modernise from LaSSo to an enterprise GMP MES platform that provides scalable master batch record management, 21 CFR Part 11 compliance and integration with quality and regulatory systems as the pipeline advances to Phase 3.

    • SOTIO manufacturing assessment, 2025

  2. ADC supply chain control tower across CDMO network

    ADC supply chains span antibody, linker and payload CDMOs with no single source of truth for inventory and status. Manual document exchange creates stockout and delay risks as manufacturing scales toward commercial volumes.

    Build an ADC supply chain control tower that provides real-time visibility into component inventory and manufacturing status across all CDMOs, enabling proactive risk identification and mitigation before supply disruptions occur.

    • SOTIO supply chain assessment, 2025

  3. Clinical-manufacturing data integration between SOTIO and SCTbio

    SOTIO and SCTbio operate bifurcated IT systems that prevent real-time visibility into manufacturing and quality data. Clinical teams make decisions without the manufacturing data that would enable proactive quality intervention and lot release acceleration.

    Integrate SOTIO and SCTbio IT systems to provide real-time visibility into manufacturing and quality data across both organisations, enabling proactive clinical decision-making and reducing the quality review cycle time for released batches.

    • SOTIO IT integration assessment, 2025

  4. Remote digital quality monitoring for distributed trial site network

    Quality oversight of 150+ apheresis centres globally requires significant on-site QA travel. As trials scale, the QA burden grows without a corresponding increase in headcount, creating a bottleneck that could delay lot release.

    Implement remote digital quality monitoring that provides real-time visibility into apheresis centre compliance status, reducing on-site QA travel requirements while improving the overall quality oversight coverage.

    • SOTIO quality operations assessment, 2025

  5. Smart facility energy optimisation for Prague manufacturing site

    PPF Group mandates sustainability targets that require demonstrated energy efficiency improvement. The Prague manufacturing site has no systematic energy monitoring or optimisation capability, making it difficult to identify reduction opportunities.

    Deploy smart facility energy monitoring and optimisation at the Prague site, providing the energy consumption baseline and reduction tracking that PPF Group sustainability reporting requires.

    • SOTIO sustainability assessment, 2025

What we'd propose

  • Digital CDMO

    MES modernisation for SOTIO Prague manufacturing site

    We modernise SOTIO's Prague manufacturing MES from LaSSo to an enterprise GMP platform that provides scalable master batch record management, 21 CFR Part 11 compliance, integration with quality and regulatory systems, and the chain of identity management required for autologous CAR-T therapy.

    • Enterprise GMP MES implementation

      Scalable manufacturing platform for Phase 3 and commercial ADC production

      Implement an enterprise GMP MES at the Prague site that provides electronic master batch records, electronic signatures, complete audit trails and 21 CFR Part 11 compliance, replacing paper-based LaSSo workflows with a system that scales to commercial manufacturing requirements.

    • Chain of identity management for CAR-T

      Complete chain of identity from apheresis to patient infusion

      Build chain of identity management that tracks every CAR-T therapy lot from apheresis through manufacturing to patient infusion, ensuring the complete chain of custody required for autologous therapy compliance.

    • MES integration with quality and regulatory systems

      Master batch records flowing directly to regulatory submissions

      Integrate the MES with SOTIO's quality management and regulatory affairs systems, enabling master batch records to flow directly into regulatory submissions and reducing the manual documentation burden for QA teams.

    • Phase 3 and commercial manufacturing scalability enabled by an MES that grows with the pipeline.
    • Regulatory inspection readiness improved by 21 CFR Part 11 compliance built into the MES rather than added on afterward.
    • QA team time recovered from paper documentation, redirected to value-added quality oversight.

    We've done this before

    See how we do Digital CDMO
  • Digital CDMO

    ADC supply chain control tower across CDMO network

    We build an ADC supply chain control tower for SOTIO that provides real-time visibility into component inventory and manufacturing status across all CDMOs — Biocytogen, Synaffix and others — enabling proactive risk identification and mitigation before supply disruptions impact manufacturing schedules.

    • Multi-CMO inventory visibility platform

      Real-time inventory across all ADC component CDMOs

      Deploy a multi-CMO inventory visibility platform that receives automated inventory updates from Biocytogen, Synaffix and other CDMOs, providing SOTIO with real-time visibility into antibody, linker and payload component availability.

    • Supply chain risk monitoring and alerting

      Supply risks identified before they become manufacturing stoppages

      Build supply chain risk monitoring that tracks lead times, CDMO capacity utilisation and quality performance, alerting SOTIO procurement when supply risks threaten manufacturing schedules.

    • Automated CDMO reporting dashboards

      CDMO performance benchmarked automatically

      Implement automated CDMO reporting dashboards that benchmark Biocytogen, Synaffix and other CDMO performance on delivery reliability, quality and cost, supporting CDMO relationship management and contract negotiations.

    • Supply disruption risk reduced by proactive visibility rather than reactive response to shortages.
    • CDMO relationship management improved by objective performance data for contract negotiations.
    • Manufacturing schedule adherence improved by inventory visibility that enables proactive component planning.

    We've done this before

    See how we do Digital CDMO
  • Enterprise AI

    Clinical-manufacturing data integration between SOTIO and SCTbio

    We integrate SOTIO and SCTbio IT systems to provide real-time visibility into manufacturing and quality data across both organisations, enabling proactive clinical decision-making, reducing the quality review cycle time for released batches and eliminating the data bifurcation that currently prevents unified operational visibility.

    • Unified manufacturing data warehouse

      SOTIO and SCTbio data in one operational platform

      Build a unified manufacturing data warehouse that consolidates data from SOTIO and SCTbio systems, providing both organisations with a single source of truth for manufacturing and quality data.

    • Real-time lot release visibility for clinical teams

      Manufacturing lot status visible to clinical teams in real time

      Implement real-time lot release visibility that notifies clinical teams when manufacturing lots are released, eliminating the communication lag between SCTbio quality completion and SOTIO clinical awareness.

    • Quality deviation escalation automation

      Quality issues escalated to the right people automatically

      Build automated quality deviation escalation that routes quality events to the appropriate SOTIO and SCTbio stakeholders based on severity, ensuring the right people are notified immediately without relying on manual communication.

    • Proactive clinical decision-making enabled by real-time manufacturing data visibility.
    • Quality review cycle time reduced by automated lot release notifications to clinical teams.
    • Organisational alignment improved by shared data platform that both SOTIO and SCTbio trust.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    Remote digital quality monitoring for SOTIO distributed trial network

    We implement remote digital quality monitoring for SOTIO's 150+ apheresis centre network that provides real-time compliance visibility, reducing on-site QA travel requirements while improving overall quality oversight coverage and accelerating lot release for CAR-T therapies.

    • Apheresis centre compliance dashboard

      Compliance status of all 150+ sites visible in one platform

      Build an apheresis centre compliance dashboard that aggregates quality indicators from all 150+ trial sites, providing SOTIO QA with real-time visibility into site compliance status without requiring on-site visits.

    • Remote QA review workflow

      QA reviews completed remotely with full audit trail

      Implement remote QA review workflow that enables SOTIO QA to review site documentation, sign off on deviations and approve corrective actions remotely, reducing QA travel requirements while maintaining full regulatory compliance.

    • Site performance benchmarking

      Apheresis centres ranked by quality and recruitment performance

      Build site performance benchmarking that ranks apheresis centres by quality compliance and patient recruitment velocity, identifying high-performing sites for expanded enrollment and struggling sites requiring intervention.

    • QA travel costs and burden reduced while quality oversight coverage is improved.
    • Lot release cycle time accelerated by remote QA review that eliminates site visit scheduling delays.
    • Site performance improved by benchmarking that identifies and addresses underperforming sites.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    Smart facility energy optimisation for Prague manufacturing site

    We deploy smart facility energy monitoring and optimisation at SOTIO's Prague manufacturing site, providing the energy consumption baseline, reduction tracking and PPF Group sustainability reporting that demonstrates progress toward mandated energy efficiency targets.

    • Sub-metered energy consumption monitoring

      Energy usage visible by equipment and process area

      Deploy sub-metered energy monitoring across all major equipment at the Prague site, providing granular visibility into energy consumption by equipment type, process area and production batch.

    • Energy efficiency benchmarking and anomaly detection

      Inefficient equipment identified automatically

      Build energy efficiency benchmarking that compares energy consumption across identical equipment and production campaigns, identifying anomalies that indicate maintenance needs or optimisation opportunities.

    • PPF Group sustainability reporting

      Automated sustainability reports meeting PPF Group requirements

      Implement automated sustainability reporting that generates the energy efficiency metrics required for PPF Group sustainability mandates, reducing the manual reporting effort while ensuring accuracy and auditability.

    • PPF Group sustainability mandates satisfied through automated, auditable energy reporting.
    • Energy reduction opportunities identified through systematic benchmarking across equipment and batches.
    • Manufacturing cost reduction achieved through energy efficiency improvements identified by the monitoring platform.

    We've done this before

    See how we do Enterprise AI

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what SOTIO Biotech a.s.'s own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
MES Capability 20 → 85
LaSSo is a niche SMB MES with five terminal PCs, paper-based hybrid workflows and no 21 CFR Part 11 validation. The system cannot scale to Phase 3 and commercial manufacturing requirements.
Supply Chain Visibility 20 → 80
ADC supply chain visibility depends on manual document exchange with CDMOs. No supply chain control tower or real-time CDMO inventory visibility is deployed.
Cross-Org Data Integration 20 → 75
SOTIO and SCTbio operate bifurcated IT systems. No unified manufacturing data platform provides cross-organisational visibility.
GMP Documentation 30 → 80
GMP documentation is partly manual with paper-based workflows. No fully digital GMP documentation system is deployed at the Prague site.
Remote Quality Oversight 20 → 70
Quality oversight of apheresis centres requires on-site QA visits. No remote digital quality monitoring is deployed for the trial site network.
Energy Management 25 → 65
No systematic energy monitoring or optimisation capability exists at the Prague manufacturing site.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with SOTIO Biotech a.s., and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].